Business & Management
Global

Business & Management Experts

Kuhn Thomas

Chief Executive Officer, Co-Founder
finance and restructuring operations
Poxel
France

Biography

Thomas  Kuhn  began  his  career  with  Merck  KGaA  in  2000  where  he  held  various  positions  in  clinical  development, mainly  in  the  therapeutic  area  of Type  2  diabetes  and   was   responsible,   in   particular,   for   forging   partnerships   with   Japanese  pharmaceutical  companies. Between 2004 and 2007, he directed Merck’s global R&D projects with  two  products  in  Phase  2  clinical  trials  and  all  the  life  cycle  management  projects  primarily  for  Glucophage®, the current reference in diabetes treatment.  Following Merck’s acquisition  of  Serono  in  2007,  Thomas  Kuhn  was  part  of  the  team  which  refined  Merck Serono’s strategy for divesting from the diabetes therapeutic area. Thomas Kuhn initiated and  concluded the project for the transfer of Merck Serono’s assets under development in Diabetes to a  new legal entity called Poxel. Since this transfer, Thomas Kuhn has been Poxel’s Chief Executive Officer. Mr. Kuhn holds a pharmacy degree from the University of Lyon I (France) and an M.B.A. from Ashridge Business School (UK). Thomas  Kuhn  began  his  career  with  Merck  KGaA  in  2000  where  he  held  various  positions  in  clinical  development, mainly  in  the  therapeutic  area  of Type  2  diabetes  and   was   responsible,   in   particular,   for   forging   partnerships   with   Japanese  pharmaceutical  companies. Between 2004 and 2007, he directed Merck’s global R&D projects with  two  products  in  Phase  2  clinical  trials  and  all  the  life  cycle  management  projects  primarily  for  Glucophage®, the current reference in diabetes treatment.  Following Merck’s acquisition  of  Serono  in  2007,  Thomas  Kuhn  was  part  of  the  team  which  refined  Merck Serono’s strategy for divesting from the diabetes therapeutic area. Thomas Kuhn initiated and  concluded the project for the transfer of Merck Serono’s assets under development in Diabetes to a  new legal entity called Poxel. Since this transfer, Thomas Kuhn has been Poxel’s Chief Executive Officer. Mr. Kuhn holds a pharmacy degree from the University of Lyon I (France) and an M.B.A. from Ashridge Business School (UK).

Research Interest

Business Development,

Global Experts from France

Global Experts in Subject

Share This Profile